Clinical trials for Myelodysplastic neoplasm with increased blasts
11 recruiting or active trials synced from ClinicalTrials.gov.
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data- RECRUITINGPhase 1NCT06616636A Phase Ib Study of Rezatapopt in Combination With Azacitidine in Patients With TP53Y220C Mutant Myeloid Malignancies (Acute Myeloid Leukemia or Myelodysplastic Syndrome)M.D. Anderson Cancer Center · PI: Courtney DiNardo, MD
- RECRUITINGPhase 1NCT06138587Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell TransplantationDana-Farber Cancer Institute · PI: Roman Shapiro, MD
- ACTIVE NOT RECRUITINGPhase 2NCT04994808Treosulfan-Based Versus Clofarabine-Based Conditioning Before Donor Hematopoietic Stem Cell Transplant for the Treatment of Myelodysplastic Syndromes or Acute Myeloid LeukemiaFred Hutchinson Cancer Center · PI: Phuong Vo
- RECRUITINGPhase 2NCT04741945Repurposing Metformin As a Leukemia-preventive Drug in CCUS and LR-MDSKirsten Grønbæk · PI: Kirsten Grønbæk, Professor, MD
- RECRUITINGPhase 1NCT04275518A Phase Ib Study of APG-115 Single Agent or in Combination With Azacitidine or Cytarabine in Patients With AML and MDS.Ascentage Pharma Group Inc. · PI: Jianxiang Wang, M.D.
- ACTIVE NOT RECRUITINGPhase 1NCT03974217Talazoparib for Cohesin-Mutated AML and MDS With Excess BlastsDana-Farber Cancer Institute · PI: Jacqueline Garcia, MD
- ACTIVE NOT RECRUITINGPhase 3NCT03682536A Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Participants Who Require Red Blood Cell Transfusions and Are ESA NaïveCelgene · PI: Bristol-Myers Squibb
- RECRUITINGPHASE1, PHASE2NCT03471260Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic MalignanciesM.D. Anderson Cancer Center · PI: Courtney DiNardo, MD
- ACTIVE NOT RECRUITINGPhase 1NCT02477878Study of Gene Modified Donor T Cell Infusion in Patients With Recurrent Disease After Allogeneic TransplantBellicum Pharmaceuticals · PI: Bellicum Pharmaceuticals
- RECRUITINGPhase 2NCT01861106Allogeneic Hematopoietic Stem Cell Transplant for GATA2 MutationsNational Cancer Institute (NCI) · PI: Danielle E Pregent-Arnold, M.D.
- ACTIVE NOT RECRUITINGNCT00899223Collecting and Storing Blood, Bone Marrow, and Other Samples From Patients With Acute Leukemia, Chronic Leukemia, or Myelodysplastic SyndromesAlliance for Clinical Trials in Oncology · PI: Michael Caligiuri, MD